942603-58-9Relevant articles and documents
QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF
-
, (2022/01/12)
Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (II), or Formula (III), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer or endometrial cancer.
KRAS G12D INHIBITORS
-
, (2021/03/05)
The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.
Discovery of selective, orally bioavailable, N-linked arylsulfonamide Nav1.7 inhibitors with pain efficacy in mice
Roecker, Anthony J.,Egbertson, Melissa,Jones, Kristen L.G.,Gomez, Robert,Kraus, Richard L.,Li, Yuxing,Koser, Amy Jo,Urban, Mark O.,Klein, Rebecca,Clements, Michelle,Panigel, Jacqueline,Daley, Christopher,Wang, Jixin,Finger, Eleftheria N.,Majercak, John,Santarelli, Vincent,Gregan, Irene,Cato, Matthew,Filzen, Tracey,Jovanovska, Aneta,Wang, Ying-Hong,Wang, Deping,Joyce, Leo A.,Sherer, Edward C.,Peng, Xuanjia,Wang, Xiu,Sun, Haiyan,Coleman, Paul J.,Houghton, Andrea K.,Layton, Mark E.
, p. 2087 - 2093 (2017/04/27)
The voltage-gated sodium channel Nav1.7 is a genetically validated target for the treatment of pain with gain-of-function mutations in man eliciting a variety of painful disorders and loss-of-function mutations affording insensitivity to pain.
